NCT06730412Completed
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to test a new liquid biopsy assay for detecting residual disease after surgery in patients with HPV-associated head and neck cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 103 (actual)
- First submitted
- 9 Dec 2024
- Start date
- 1 Aug 2020
- Primary completion date
- 31 Oct 2024
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Diseases
- Head and neck cancer
- NCT number
- NCT06730412
What you commit to
- Study type: Observational
- Participants enrolled: 103
- From 1 Aug 2020 to the primary completion date, 31 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving treatment for concurrent second malignancy
Other
- Not meeting all inclusion criteria
- Pregnant
Who the study is looking for
- Greater than or equal to 18 years of age
- Newly diagnosed, untreated, histologically confirmed HPV-associated head and neck cancer
- Scheduled for curative intent resection as primary treatment
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.